Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to -$25.5 million.

  • Arcutis Biotherapeutics' Net Cash Flow fell 15056.16% to -$25.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$87.9 million, marking a year-over-year decrease of 42555.08%. This contributed to the annual value of -$17.1 million for FY2024, which is 14967.24% down from last year.
  • Per Arcutis Biotherapeutics' latest filing, its Net Cash Flow stood at -$25.5 million for Q3 2025, which was down 15056.16% from $19.1 million recorded in Q2 2025.
  • Over the past 5 years, Arcutis Biotherapeutics' Net Cash Flow peaked at $223.6 million during Q1 2021, and registered a low of -$199.6 million during Q2 2021.
  • Moreover, its 5-year median value for Net Cash Flow was -$8.3 million (2022), whereas its average is -$1.0 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first plummeted by 93148.81% in 2021, then surged by 197578.12% in 2024.
  • Arcutis Biotherapeutics' Net Cash Flow (Quarter) stood at $44.7 million in 2021, then crashed by 162.46% to -$27.9 million in 2022, then soared by 31.4% to -$19.1 million in 2023, then plummeted by 230.61% to -$63.3 million in 2024, then soared by 59.66% to -$25.5 million in 2025.
  • Its last three reported values are -$25.5 million in Q3 2025, $19.1 million for Q2 2025, and -$18.2 million during Q1 2025.